on March 6, 2017
Jo, congratulations with this amazing achievement of your R&D team at Biogazelle. Tell us, why are you so excited about the work you have done? What we offer today is …
Read moreon March 24, 2016
The 'Survival Associated Mitochondrial Melanoma Specific ONcogenic RNA' is a long non-coding RNA that is specifically expressed in malignant melanoma cells, and not in other normal human cells or other …
Read moreon November 5, 2015
Exiqon A/S (NASDAQ OMX: EXQ), a leading provider of flexible solutions for RNA analysis, today announced the impressive results of a comparative study on technologies for functional knockdown. The study …
Read moreon October 20, 2015
MARLBOROUGH, Mass., Oct. 20, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology …
Read moreon October 15, 2015
Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet …
Read moreon August 12, 2015
Biogazelle today announced that it has received €1.1M in funding from the agency for Innovation by Science and Technology (IWT) in Flanders to leverage its cancer therapy development program, focused …
Read moreon June 12, 2015
Biogazelle has a longstanding track record and internationally recognized expertise in RNA gene expression analysis, with a particular focus on non-coding RNA, such as microRNAs and long non-coding RNAs. Today, …
Read moreon February 6, 2015
On October 6, 2014, Biogazelle announced the closure of an investment round with QBIC Arkiv Fund, Foundation Majoie and SOFI to finance its growth (press release available on http://bgzlle.com/2bCDGtm). Today, Biogazelle …
Read moreon January 27, 2015
Biogazelle is a Ghent University spin-off company founded in 2007 by prof. Jo Vandesompele and dr. Jan Hellemans. With a proven track record in gene expression studies, Biogazelle is at …
Read moreon October 6, 2014
Qbic Arkiv Fund, Foundation Majoie and SOFI invest 2.0 million EUR in UGent spin-off Biogazelle, a company that offers software and laboratory services for gene expression analysis. Biogazelle will primarily …
Read moreTechnologiepark 82
B-9052 Zwijnaarde
Belgium
email: info@biogazelle.com
phone: +32 9 245 96 43
fax: +32 9 251 56 56
